TrendsinPsychotropicPolypharmacy AmongYouthsEnrolledinOhio Medicaid,2002-2008

Objective: This study examined polypharmacy patterns and rates over time among Medicaid-enrolled youths by comparing three enrollment groups (youths in foster care, with a disability, or from a family with low income). Methods: Serial cross-sectional trend analyses of Medicaid claims data were conducted for youths age 17 and younger who were continuously enrolled in Ohio Medicaid for a one-year period and prescribed one or more psychotropic medications during fiscal years 2002 (N=26,252) through 2008 (N=50,311). Outcome measures were any polypharmacy (three or more psychotropic medications from any drug class) and multiclass polypharmacy (three or more psychotropic medications from different drug classes). Results: Both types of polypharmacy increased across all three eligibility groups. Any polypharmacy increased from 8.8% to 11.5% for low-income youths (adjusted odds ratio [AOR]= 1.12, 99% confidence interval [CI]=1.10–1.13), from 18.0% to 24.9% for youths with a disability (AOR=1.11, CI=1.09–1.13), and from 19.8% to 27.3% for youths in foster care (AOR=1.09, CI=1.07–1.11). Combinations associated with positive increases were two or more antipsychotics, two or more stimulants, and antipsychotics with stimulants. Conclusions: Polypharmacy increased across all enrollment groups, with the highest absolute rates for youths in foster care. Both the overall prevalence and increases in prescriptions for drug combinations with limited evidence of safety and efficacy, such as the prescription of two or more antipsychotics, underscore the need for targeted quality improvement efforts. System oversight and monitoring of psychotropic medication use appears to be warranted, especially for higher-risk groups, such as youths in foster care and those from low-income households who were prescribed multiple antipsychotics. (Psychiatric Services 65:1332–1340, 2014; doi:

[1]  M. Olfson,et al.  National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. , 2012, Archives of general psychiatry.

[2]  R. Aparasu,et al.  The definition and prevalence of pediatric psychotropic polypharmacy. , 2011, Psychiatric services.

[3]  M. Riddle,et al.  Antipsychotic Treatment Among Youth in Foster Care , 2011, Pediatrics.

[4]  M. Olfson,et al.  National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  T. Boaz,et al.  Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. , 2010, Clinical therapeutics.

[6]  J. Lieberman,et al.  Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. , 2009, Psychiatric services.

[7]  Barbara Napolitano,et al.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.

[8]  M. Olfson,et al.  Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. , 2009, Health affairs.

[9]  C. Feudtner,et al.  State Variation in Psychotropic Medication Use by Foster Care Children With Autism Spectrum Disorder , 2009, Pediatrics.

[10]  C. Correll,et al.  Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. , 2009, Schizophrenia bulletin.

[11]  R. McIntyre,et al.  Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. , 2009, The Journal of clinical psychiatry.

[12]  R. McIntyre,et al.  Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. , 2008, Archives of pediatrics & adolescent medicine.

[13]  J. Oldham,et al.  When is antipsychotic polypharmacy supported by research evidence? Implications for QI. , 2008, Joint Commission journal on quality and patient safety.

[14]  D. Safer,et al.  Psychotropic Medication Patterns Among Youth in Foster Care , 2008, Pediatrics.

[15]  Jill U. Adams,et al.  Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. , 2008, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  C. Arango,et al.  Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. , 2007, Journal of child and adolescent psychopharmacology.

[17]  S. Benjamin,et al.  Dystonia with combined antipsychotic and stimulant treatment. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[18]  C. Correll Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[19]  Brett W Sharp Cmap ADHD and comorbid aggression algorithm. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[20]  J. Swanson,et al.  The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[21]  M. Monuteaux,et al.  Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[22]  Imke H. Bartelink,et al.  Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations , 2006, Clinical pharmacokinetics.

[23]  B. Kerker,et al.  Mental health needs and treatment of foster youth: barriers and opportunities. , 2006, The American journal of orthopsychiatry.

[24]  M. Crismon,et al.  Trends in the use of typical and atypical antipsychotics in children and adolescents. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  E. Benjamin,et al.  Stimulant-atypical antipsychotic interaction and acute dystonia. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  H. Pincus,et al.  Concomitant pharmacotherapy among youths treated in routine psychiatric practice. , 2005, Journal of child and adolescent psychopharmacology.

[27]  P. Owens,et al.  Multiple psychotropic medication use for youths: a two-state comparison. , 2005, Journal of child and adolescent psychopharmacology.

[28]  S. Gaehde,et al.  Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database , 2005, Pharmacoepidemiology and drug safety.

[29]  R. Surles,et al.  Using best practices to manage psychiatric medications under Medicaid. , 2004, Psychiatric services.

[30]  A. Localio,et al.  Placement Changes and Emergency Department Visits in the First Year of Foster Care , 2004, Pediatrics.

[31]  L. Leslie,et al.  Outpatient mental health services for children in foster care: a national perspective. , 2004, Child abuse & neglect.

[32]  S. Stahl Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? , 2004, The international journal of neuropsychopharmacology.

[33]  B. Vitiello,et al.  National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge , 2004, Journal of attention disorders.

[34]  A. Localio,et al.  Placement stability and mental health costs for children in foster care. , 2004, Pediatrics.

[35]  A. Garland,et al.  Racial/ethnic disparities in mental health service use among children in foster care , 2003 .

[36]  D. Safer,et al.  Concomitant psychotropic medication for youths. , 2003, The American journal of psychiatry.

[37]  M. Jellinek Mirror, mirror on the wall: are we prescribing the right psychotropic medications to the right children using the right treatment plan? , 2003, Archives of pediatrics & adolescent medicine.

[38]  M. Weissman,et al.  National trends in the use of psychotropic medications by children. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[39]  R. Schweitzer,et al.  "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. , 2002, Schizophrenia bulletin.

[40]  G. Simpson,et al.  Psychopharmacology: rational and irrational polypharmacy. , 2001, Psychiatric services.

[41]  K. Soeken,et al.  Mental health services for youths in foster care and disabled youths. , 2001, American journal of public health.

[42]  K. Kelleher,et al.  Mental health care utilization and expenditures by children in foster care. , 2000, Archives of pediatrics & adolescent medicine.

[43]  J. Woolston Combined pharmacotherapy: pitfalls of treatment. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[44]  D. Connor,et al.  Combined pharmacotherapy in children and adolescents in a residential treatment center. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[45]  J. Biederman,et al.  Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[46]  A. Bergman,et al.  Children in foster care in the state of Washington. Health care utilization and expenditures. , 1994, JAMA.